CapsoVision submitted a 510(k) application for its AI-assisted module to enhance its CapsoCam Plus endoscopy system.
Quiver AI Summary
CapsoVision, Inc. has submitted a 510(k) application to the FDA for its AI-assisted module designed for the CapsoCam Plus capsule endoscopy system, which aims to enhance the detection of clinically significant gastrointestinal pathology while also reducing clinician review time. The company anticipates beginning commercialization in the U.S. following FDA clearance. CapsoCam Plus is specifically developed for visualizing the small bowel in both adults and children over two years old, with CapsoVision claiming it surpasses competitor systems in image capturing and presentation. The company highlights its in-house AI capabilities and cloud-based architecture, which improves diagnostic efficiency and accessibility. CapsoVision is focused on advancing its technology pipeline, including the upcoming CapsoCam Colon, for non-invasive colon imaging and disease detection.
Potential Positives
- CapsoVision submitted its 510(k) application for its AI-assisted module for CapsoCam Plus®, positioning itself for potential FDA clearance and subsequent U.S. commercialization.
- The company believes its CapsoCam Plus® system offers advanced imaging capabilities that could enhance the detection of gastrointestinal pathologies compared to competitors.
- CapsoVision's proprietary AI core competency and cloud-based architecture are designed to improve efficiency, accuracy, and accessibility in gastrointestinal diagnostics.
Potential Negatives
- The company's future results and regulatory approval timeline are uncertain, as highlighted by the emphasis on significant risks and uncertainties in their forward-looking statements.
- There is no assurance of FDA clearance for the new AI-assisted module, which could hinder market entry and commercialization efforts.
- The statement regarding being the only capsule endoscopy company with in-house AI core competency may raise skepticism or competitive concerns in the rapidly evolving medical technology landscape.
FAQ
What is CapsoVision's recent FDA submission about?
CapsoVision submitted a 510(k) application for its AI-assisted module for CapsoCam Plus® to enhance pathology detection and reduce review time.
What does the CapsoCam Plus® system do?
CapsoCam Plus® is a capsule endoscopy system designed to visualize and detect abnormalities in the small bowel for patients aged two and older.
How is CapsoVision different from competitors?
CapsoVision claims to have in-house AI capabilities and offers a more advanced imaging solution with a fully cloud-based architecture.
When will CapsoVision commercialize its AI module?
CapsoVision plans to begin U.S. commercialization activities after receiving FDA clearance for their AI-assisted module.
What future products is CapsoVision developing?
CapsoVision is developing CapsoCam Colon™, an enhanced AI system for non-invasive colon imaging and polyp detection.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CV Hedge Fund Activity
We have seen 26 institutional investors add shares of $CV stock to their portfolio, and 0 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GEODE CAPITAL MANAGEMENT, LLC added 115,033 shares (+inf%) to their portfolio in Q3 2025, for an estimated $556,759
- VANGUARD GROUP INC added 69,575 shares (+inf%) to their portfolio in Q3 2025, for an estimated $336,743
- BLACKROCK, INC. added 58,765 shares (+inf%) to their portfolio in Q3 2025, for an estimated $284,422
- NORTHERN TRUST CORP added 42,868 shares (+inf%) to their portfolio in Q3 2025, for an estimated $207,481
- CITADEL ADVISORS LLC added 23,735 shares (+inf%) to their portfolio in Q3 2025, for an estimated $114,877
- STATE STREET CORP added 19,500 shares (+inf%) to their portfolio in Q3 2025, for an estimated $94,380
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 14,091 shares (+inf%) to their portfolio in Q3 2025, for an estimated $68,200
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CV Analyst Ratings
Wall Street analysts have issued reports on $CV in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Benchmark issued a "Speculative Buy" rating on 07/28/2025
To track analyst ratings and price targets for $CV, check out Quiver Quantitative's $CV forecast page.
Full Release
SARATOGA, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced submission of its 510(k) application to the Food and Drug Administration (FDA) for its proprietary AI-assisted module for CapsoCam Plus®. The addition of this reading tool will improve the detection of clinically significant pathology, as well as reduce clinician review time. The Company intends for U.S. commercialization activities to commence after the FDA clearance.
CapsoVision’s CapsoCam Plus capsule endoscopy system is intended for visualization of the small bowel mucosa to detect abnormalities of the small bowel in adults and children aged two years and older. The Company believes that it is a more advanced capsule endoscopy solution compared to competitor systems, both in how it captures and presents images of the GI tract and the clinical workflow and patient experience that it enables.
“This submission marks an important milestone in our commitment to customers and patients towards advancing a best-in-class solution that integrates advanced imaging with AI-powered interpretation for small bowel diagnostics,” said Johnny Wang, President and Chief Executive Officer. “We believe we are the only capsule endoscopy company with in-house AI core competency, and the scale and quality of our growing image data trove create a powerful foundation for training AI models and uncovering new clinical insights that will set our platform apart from competitive options. Combined with our fully cloud-based architecture—which eliminates the need for on-site servers, reduces cost and downtime, and removes the burden of IT maintenance—we are delivering an AI-enabled diagnostic platform designed to bring efficiency, accuracy, and accessibility to GI practices of all sizes.”
About CapsoVision
CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and diagnosis of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company’s next pipeline product, CapsoCam Colon™ with enhanced AI, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit
www.capsovision.com
.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as “expected”, “anticipates”, “intends”, “plans”, “believes”, “potential”, “will”, “should”, “could”, “would” or “may” and other words of similar meaning. Examples of these forward-looking statements include, but are not limited to, statements concerning possible or assumed future results of operations, including the timing and receipt of regulatory approvals, the Company’s plans, strategies and timing for its pipeline development, and the success of the Company’s plans and strategies. These forward-looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties, including those beyond the Company’s control. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, market conditions and the failure to receive regulatory clearance. These and other risks and uncertainties are described more fully in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s prospectus filed on July 3, 2025 with the SEC, as part of the Company’s Registration Statement on Form S-1 (File No. 333-287148), and the Company’s most recent Form 10-Q. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise these statements, except as required by law.
Investor Relations Contact
Leigh Salvo
New Street Investor Relations
[email protected]
Media Contact
Leslie Strickler and Paul Spicer
Être Communications
[email protected]
| (804) 240-0807
[email protected]
| (804) 503-9231
